Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Part of paid clinical trials in Fountain Valley, California.
- Sponsor
- GlaxoSmithKline
- Study ID
- NCT04655976
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Lung Cancer, Non-Small Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cobolimab — BIOLOGICALCobolimab will be administered.
- Dostarlimab — BIOLOGICALDostarlimab will be administered.
- Docetaxel — DRUGDocetaxel will be administered.
Study Details
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Key Dates
- Start date
- Dec 8, 2020
- Status verified
- Sep 2025
- Primary completion
- Jun 5, 2025
- Completion
- Mar 30, 2027
Study Design
- Enrollment
- 758 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Participants receiving cobolimab+ dostarlimab+ docetaxel
- Experimental: Participants receiving dostarlimab+ docetaxel
- Active Comparator: Participants receiving docetaxel
Primary Outcome Measure
Overall survival (OS) in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving docetaxel alone [ Time Frame: Up to approximately 52 months ]
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| GSK Investigational Site | Fountain Valley | California | 92708 | - |
| GSK Investigational Site | Walnut Creek | California | 94596 | - |
| GSK Investigational Site | Norwich | Connecticut | 06360 | - |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20422 | - |
| GSK Investigational Site | Honolulu | Hawaii | 96819 | - |
| GSK Investigational Site | Iowa City | Iowa | 52242 | - |
| GSK Investigational Site | Edgewood | Kentucky | 41017 | - |
| GSK Investigational Site | Las Vegas | Nevada | 89144 | - |
| GSK Investigational Site | Mineola | New York | 11501 | - |
| GSK Investigational Site | New York | New York | 10016 | - |
| GSK Investigational Site | White Plains | New York | 10601 | - |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15224 | - |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15232 | - |
| GSK Investigational Site | Sioux Falls | South Dakota | 57105 | - |
| GSK Investigational Site | Houston | Texas | 77030 | - |
| GSK Investigational Site | Fredericksburg | Virginia | 22408 | - |
| GSK Investigational Site | Tacoma | Washington | 98405 | - |
Find similar trials in Fountain Valley, CA
Related Studies
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPHASE1/PHASE2 · Recruiting · Krystal Biotech, Inc. · Dothan, Alabama
- Engagement of Veterans With Lung CancerRecruiting · Palo Alto Veterans Institute for Research · Palo Alto, California